<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959435</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2021 ANDRE</org_study_id>
    <secondary_id>2021-A01648-33</secondary_id>
    <nct_id>NCT04959435</nct_id>
  </id_info>
  <brief_title>Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)</brief_title>
  <acronym>BEHCETBIOT</acronym>
  <official_title>Understanding the Role of the Salivary Microbiota and Microbiota Associated to Mucosa in Behçet's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Behçet's disease (BD) is a systemic vasculitis that affects, especially, young people.&#xD;
&#xD;
      Although its etiology remains unexplained, data suggest that the inflammatory response during&#xD;
      BD results from a disruption of the homeostasis of innate and adaptive immune responses in&#xD;
      genetically predisposed people. The microbiota could play a triggering role in BD, in&#xD;
      particular the salivary and dental plaque microbiota. The aim of the Behçetbiot study is&#xD;
      therefore to establish microbial profiles of dental plaque, pathological (on the mouth ulcer)&#xD;
      and non-pathological mucous membrane, salivary and digestive and to compare them with control&#xD;
      subjects not suffering from BD, related to the first degree, of the same socio-cultural level&#xD;
      and to determine whether dysbiosis is correlated with a local and systemic pro-inflammatory&#xD;
      response, by measuring salivary level of pro-inflammatory cytokines and blood level of CRP,&#xD;
      fibrinogen, orosomucoïd and haptoglobin, and to compare them with controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients and their controls are sampled for stool, saliva, dantal plaque, oral mucosa,&#xD;
      genital mucosa and blood during an annual follow-up visit or if they are hospitalised.&#xD;
&#xD;
      Plaque, oral mucosa, genital mucosa salivary and blood will be collected during an annual&#xD;
      follow-up visit.&#xD;
&#xD;
      For stool samples, the collection material will be provided to the patient and they will be&#xD;
      able to take the sample at home and bring it to the clinic, or send them via a carrier within&#xD;
      3 days.&#xD;
&#xD;
      All the samples related to the study will be taken in the internal medicine in&#xD;
      Clermont-Ferrand (France) or Pitie Salpêtrière, department of internal medecine, Paris,France&#xD;
      or ophthalmology departments in Clermont-Ferrand.&#xD;
&#xD;
      All sample will be stocked in biological center in Clermont-Ferrand before analyze.&#xD;
&#xD;
      Microbiota analyzes will be realise at M2iSH laboratoty, inflammatory cytokines will be&#xD;
      analyze in Clermont-Ferrand immunology laboratory, and pro-inflammatory parameters will be&#xD;
      analyse in biochimy laboratory in Clermont-Ferrand.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 22, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oral microbiota</measure>
    <time_frame>Day 0</time_frame>
    <description>Establish microbial profiles (quantitative and qualitative via analysis of bacterial DNA sequences encoding 16S rRNA) of dental plaque, pathological (on the aphta) and non-pathological oral mucosa and and salivary and compared them to control without Behçet's disease matched for sex, diet and socio-cultural level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>Day 0</time_frame>
    <description>Establish microbial profiles (quantitative and qualitative via analysis of DNA sequences encoding 16S rRNA) of the intestinal microbiota by studying feces and comparing them to controls without Behçet's disease, of the same sex, diet and socio-cultural level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short fatty acid</measure>
    <time_frame>Day 0</time_frame>
    <description>Determination of short-chain fatty acids (HPLC technique) in the stools of Behçet patients and compare them to control patients without Behçet's disease, of the same sex, diet and socio-cultural level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory cytokines</measure>
    <time_frame>Day 0</time_frame>
    <description>Determination of blood and saliva levels of IL-1beta, IL-6, IL-17, IL21, IL-23, Il-10, IFN gamma and TNF alpha (ELISA technique or multiplexed assay) and compare them to patients without Behçet disease, of the same sex, diet and socio-cultural level.&#xD;
socio-cultural level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genital microbiota</measure>
    <time_frame>Day 0</time_frame>
    <description>Establish microbial profiles (quantitative and qualitative via analysis of DNA sequences encoding 16S rRNA) of the intestinal microbiota by studying feces and comparing them to controls without Behçet's disease, of the same sex, diet and socio-cultural level</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Behçet Disease</condition>
  <condition>Physiopathology</condition>
  <condition>Microbiota</condition>
  <condition>Oral Microbiota</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Behcet's disease patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Controls that matched two to two at case according to sex,social status and diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological samples collection</intervention_name>
    <description>samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who have behçet's disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who meet the International criteria for the classification of Behçet's&#xD;
             disease, revised in 2013)&#xD;
&#xD;
          -  Patient who had developed the disease in the 5 years preceding the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women, or women who may be pregnant or breastfeeding.&#xD;
&#xD;
          -  Subject placed under judicial protection.&#xD;
&#xD;
          -  Patient had received antibiotic or probiotic or symbiotic therapy in the 6 weeks&#xD;
             preceding inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marc André</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>+33473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data are reserved for M2ISH laboratory team .</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

